VFC's Stock House, Stocks In The Spotlight: Amarin and Neostem
(EMAILWIRE.COM, September 7, 2012 ) New York, NY -- Amarin (AMRN) and Neostem (NBS) are two companies making major moves this week that investors should take note of, as outlined by VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, at the VFCsStockHouse.com website.
Shares of Amarin Corporation opened the new trading week with a bang, jumping by over a buck on Tuesday - good for a seven percent gain - before giving back half of those gains on Wednesday as traders likely parlayed the quick spike into some opportune profits. Amarin has been one of the more-watched stories in the healthcare sector over the summer, especially since the late-July approval of Vascepa for the treatment of very high trigylcerides sent shares into a dramatic tailspin that resulted in a twenty percent drop in price. Although shares did begin to rebound rather quickly, investors - and potential buyers of the company - were still awaiting the outcome of pending catalysts that could confirm the true overall value of Vascepa over both the short and long terms. One of those catalysts developed this week and led to Tuesday's share price spike of seven percent.
Amarin announced this week that the United States Patent and Trademark Office (USPTO) has published notification of Notices of Allowance for multiple U.S. Patent Applications that will significantly strengthen the protection of Vascepa from competition until at least 2030. While many expected that the slew of Amarin's patent applications would start receiving such notices in due time, the realization of those expectations adds the validation needed for investors and potential buyers of the company to accurately gauge the potential value of the product over time. Given that many see Vascepa as a potential blockbuster - once approved for all indications of high triglycerides - the added protection may add billions to the value of a potential buyout deal.
Also on the horizon is the expected decision on Vascepa's status as a new chemical entity (NCE). Such an approval would again provide added protection for the product and validate the true long term value of the product.
Neostem Inc is another company in the healthcare sector making a major move in the healthcare sector this week. Shares of this developmental company developing a pipeline of stem cell therapies moved by thirteen percent on Wednesday as the company prepares to embark on a road show that will put its developmental stem cell therapies in the spotlight at five major investor conferences. The busy schedule commences this week in New York where Neostem representatives will present at the 19th Annual Newsmakers in the Biotech Industry - BioCentury & Thomson Reuters.
While investor conferences are a great way to build exposure for a developmental company, competition for investor interest is thick - so there must be a story to tell. For Neostem, a company positioning itself as a leader in the field of regenerative medicine, the story could be gaining enough momentum to quickly become exciting, as evidenced by this week's price run and the run that materialized earlier this year that led to a share price double.
NeoStem's most advanced therapy candidate, AMR-001, is targeting the multi-billion dollar market of preventing major cardiac events following acute myocardial infarction (AMI). According to estimations by NeoStem in a recent company report, numbers also cited by the American Heart Association, of the roughly 800,000 annual AMI patients, about 20% are considered ST segment elevation myocardial infarction (STEMI), a condition that places patients at risk to experience conditions of progressively deteriorating heart function. It is that 20% of patients who will be systematically targeted for treatment via Neostem's ongoing PreSERVE trial. In an early sign of validation, an independent data monitoring committee reported last month that the company had received approval to continue moving forward with the trial.
While not a telling sign of overall success, it is validation enough that the treatment may be working as intended.
Follow Amarin, Neostem and other hot stocks at VFCsStockHouse.com.
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.